DCF Analysis Suggests Edwards Lifesciences Is Overvalued by ~41%

What happened

A new DCF analysis from GuruFocus calculates Edwards Lifesciences' intrinsic value at $48 per share, well below the current trading price of $81.53, implying significant overvaluation. This stark valuation gap contrasts with the company's recent operational momentum, including Q3 2025 TAVR growth of 12.4% YoY and raised 2026 EPS guidance to $2.90–$3.05. However, the DeepValue report's base case, which assumes 6–8% TAVR growth and successful TMTT scaling, implies a value of ~$90, suggesting the DCF may be too pessimistic about long-term growth or margin assumptions. The bear case in the report values the stock at $70, still above the DCF's $48, indicating that even under adverse scenarios, the DCF implies a risk of further downside if growth disappoints. Investors should view the DCF as a cautionary signal that the market is pricing in optimistic growth assumptions, but the wide divergence from the report's scenarios highlights the uncertainty in forecasting long-term cash flows for a high-growth med-tech.

Implication

While the DCF may be overly conservative given guideline tailwinds and TMTT potential, it reinforces the need for disciplined entry; waiting for a pullback toward $72–$75 offers a more attractive risk/reward.

Thesis delta

The DCF introduces a more extreme bearish perspective than the report's base case, lowering the implied floor; investors should now weigh the possibility that the market's growth assumptions are overly optimistic, and the stock could face material downside if execution falters, making the WAIT stance even more appropriate.